Wave Life Sciences Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
WAVE Life Sciences (WVE) Misses Q2 EPS by 22c, Revenues Miss
March 2, 2020 6:46 AM ESTWAVE Life Sciences (NASDAQ: WVE) reported Q2 EPS of ($1.65), $0.22 worse than the analyst estimate of ($1.43). Revenue for the quarter came in at $2.4 million versus the consensus estimate of $5.52 million.
We continue to advance our innovative, CNS-focused pipeline of stereopure oligonucleotides across Huntingtons disease, amyotrophic lateral sclerosis, frontotemporal dementia and other central nervous system diseases. Despite the disappointment of discontinuing our Duchenne program last year, we are advancing more than a dozen... More
